All In Biotech

Drug Trial Radar · NCT07132957

A Study of AL8326 in Healthy Subjects

A Phase I Study to Evaluate the Mass Balance of 14C-labeled AL8326 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Feb 21, 2025

Primary completion

May 17, 2025

Study completion May 17, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard. On the first day of the experiment, each subject orally took a single dose of \[14C\] AL8326 oral formulation containing approximately 60mg (200 μ Ci). During the experiment, whole blood, plasma, urine, and fecal samples were collected at designated time points/time periods.

Conditions

  • Small Cell Lung Cancer
  • Solid Tumors

Interventions

  • 14C-labeled AL8326Drug

    Oral, About 60mg (200μCi) of 14C-labeled AL8326

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Material balanceTime frame: All excreted urine and feces samples at specified time points during 0-480 hours after dosing will be collected.
  2. MetabolitesTime frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol
  3. MetabolitesTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol
  4. PharmacokineticTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol
  5. whole bloodTime frame: Conduct testing within 1 month after all subjects collect plasma samplesat all time points required by the protocol

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.